Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Neuro-HAART in Patients With HIV

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV positive with nadir cluster of differentiation 4 (CD4) count \<350 /microlitre (uL)~* Taking HAART with CNS Penetration Effectiveness (CPE) score of either ≤7.0 or ≥7.5 for 1 year or more. Changes in antiretrovirals (ARVs) within the last 12 months are allowed so long as the CPE score does not lead to a change groups~* Plasma HIV viral load \<50 copies / mL for preceding 12 months or longer~* Informed consent given by participant or legally appointed guardian~Exclusion Criteria:~* Non-HIV related neurological disorders and active CNS opportunistic infection as assessed by full blood count, electrolytes, creatinine, glucose, liver function tests, cryptococcal antigen, venereal disease reaction level (VDRL), MRI brain scan and cerebrospinal fluid analyses for cell count, protein, glucose, culture, VDRL and cryptococcal antigen.~* Psychiatric disorders on the psychotic axis, current major depression, and current substance use disorder as assessed by the Study Enrolment Questionnaire for Eligibility~* Severe substance use disorders (within 12 months of study entry)~* Active Hepatitis C virus (HCV) (detectable HCV RNA because HCV per se can cause cognitive impairment)~* History of loss of consciousness \>1 hour~* Non-proficient in English as assessed by the English as a second language questionnaire~* Medications known pharmacologically to interact with ARVs~* Pregnancy as assessed by the urinary pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non Neuro-HAART (low CNS penetrance) (Type: None): Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
- Neuro-HAART (high CNS penetrance) (Type: None): Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).